These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14672521)

  • 21. Collaborative Counseling Considerations for Pharmacogenomic Tests.
    Zierhut HA; Campbell CA; Mitchell AG; Lemke AA; Mills R; Bishop JR
    Pharmacotherapy; 2017 Sep; 37(9):990-999. PubMed ID: 28672074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Informed consent in the context of pharmacogenomic research: ethical considerations.
    Howard HC; Joly Y; Avard D; Laplante N; Phillips M; Tardif JC
    Pharmacogenomics J; 2011 Jun; 11(3):155-61. PubMed ID: 21445091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report.
    Corrigan OP
    J Med Ethics; 2005 Mar; 31(3):144-8. PubMed ID: 15738433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finding a liability-free space in which personalized medicine can bloom.
    Evans BJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):461-5. PubMed ID: 17713468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomic data sample collection and storage: ethical issues and policy approaches.
    Joly Y; Knoppers BM
    Pharmacogenomics; 2006 Mar; 7(2):219-26. PubMed ID: 16515401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Racializing drug design: implications of pharmacogenomics for health disparities.
    Lee SS
    Am J Public Health; 2005 Dec; 95(12):2133-8. PubMed ID: 16257939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.
    van Delden J; Bolt I; Kalis A; Derijks J; Leufkens H
    Bioethics; 2004 Aug; 18(4):303-21. PubMed ID: 15449404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Privacy issues in personalized medicine.
    Vaszar LT; Cho MK; Raffin TA
    Pharmacogenomics; 2003 Mar; 4(2):107-12. PubMed ID: 12605543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics.
    Schiavone S; Neri M; Pomara C; Riezzo I; Trabace L; Turillazzi E
    Curr Pharm Biotechnol; 2017; 18(3):253-262. PubMed ID: 28176639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ethical implications of stratifying by race in pharmacogenomics.
    Lee SS
    Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethical, social and legal implications of pharmacogenomics: a critical review.
    Moldrup C
    Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics and ethical considerations: why care?
    Marx-Stölting L
    Pharmacogenomics J; 2007 Oct; 7(5):293-6. PubMed ID: 17033614
    [No Abstract]   [Full Text] [Related]  

  • 33. Ethical implications of pharmacogenetics--do slippery slope arguments matter?
    Schubert L
    Bioethics; 2004 Aug; 18(4):361-78. PubMed ID: 15449407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethical perspectives on pharmacogenomic profiling in the drug development process.
    Issa AM
    Nat Rev Drug Discov; 2002 Apr; 1(4):300-8. PubMed ID: 12120281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
    Bashir NS; Ungar WJ
    Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored medicine: whom will it fit? The ethics of patient and disease stratification.
    Smart A; Martin P; Parker M
    Bioethics; 2004 Aug; 18(4):322-42. PubMed ID: 15449405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protecting communities in pharmacogenetic and pharmacogenomic research.
    Weijer C; Miller PB
    Pharmacogenomics J; 2004; 4(1):9-16. PubMed ID: 14647406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics - therapeutic and ethical issues.
    Patowary S
    Kathmandu Univ Med J (KUMJ); 2005; 3(4):428-30. PubMed ID: 16449851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.